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INTRODUCTION 61 62
Candida species cause distressing mucocutaneous infections of the integument, oral and 63 genitourinary tracts. Vulvovaginal candidiasis is estimated to occur in 50-75% of women in their 64 childbearing years (1-3) and recurrence of vulvovaginal candidiasis (RVVC) is common (4). 65 Hematogenously disseminated candidiasis is a life-threatening condition of increasing incidence 66 in recent decades (1). Despite the use of antifungal therapy, candidemia is associated with ~40% 67 attributable mortality (5) . Compounding these concerns is the alarming rise in emergence of 68 Candida species resistant to antifungal drugs (6) . 69 70 C. albicans has multiple putative virulence capabilities including avid adherence to abiotic and 71 host surfaces (7), the capacity to produce tissue-invading filaments (hyphae) (8), and the 72 development of biofilms that promote immune evasion and impede efficacy of antifungal therapy 73 (6). Targeting of these key virulence mechanisms provides opportunities for developing novel 74 therapeutic interventions with minimal effects on the host mycobiome, and reduction in selection 75 pressures that favor drug resistance (9).
77
NDV-3 is a vaccine containing a His-tagged recombinant version of the C. albicans Als3 protein 78 (Als3p) N-terminus formulated with alum. Expressed on C. albicans hyphae, Als3p promotes 79 adhesion of the fungus to biotic and abiotic substrates, enables invasion of host cell tissues, and 80 facilitates biofilm formation (10, 11) . Deletion of the Als3 gene significantly impairs these 81 virulence traits of C. albicans in vitro (10, 11) . Consistent with these themes, NDV-3 decreases 82 disease severity caused by Candida species in mice (12-15).
84
A Phase 1 clinical trial in healthy adults demonstrated safety and immunogenicity of the NDV-3 85 vaccine as evidenced by robust antibody and T-cell immune responses (13). Furthermore, a single 86 dose of NDV-3A (rAls3p without the His-tag and formulated with alum) administered 87 intramuscularly was safe and induced strong antibody and T-cell immune responses in patients 88 with RVVC in a recent exploratory Phase 1b/2a study. This immune response protected patients 89 <40 years of age with a history of RVVC from recurrence over a twelve-month study period (16).
90
Specifically, post-hoc exploratory analysis revealed a statistically significant increase in the 91 percent of the symptoms-free patients at twelve months post vaccination (42% vaccinated vs. 22% 92 placebo; p=0.029) and a doubling time to first symptomatic episode (210 days vaccinated vs. 105 93 days placebo) for the subset for the patients <40 years of age (n=137).
95
The objective of the current study is to investigate the role of Als3p antibodies induced by NDV-96 3A as biomarkers of vaccine efficacy by quantitative and qualitative analysis of antibody titers and 97 by evaluating the effect of these antibodies on C. albicans virulence traits. 
Serum Samples

103
All sera used in this study were prepared from blood collected from NDV-3A or placebo recipients 104 in a Phase 1b/2a study in women with RVVC (ClinicalTrials.gov access number, NCT01926028) 105 (16) using previously described methods (13) and were stored at -80 o C until analyzed. Sera were 106 obtained from 64 of 66 NDV3-A recipients and 53 of 60 placebo recipients using appropriate 107 collection, processing and storage practices. In the NDV3-A group, 27 patients had no recurrence 108 of VVC during the 12-month follow-up period and were classified as "non-recurrent" (NR), while 109 37 patients had one or more recurrences of VVC and were designated "recurrent" (R). For the 110 placebo group, only 7 patients were classified as NR, while the rest were classified as R. Because 111 of the low number of NR patients in the placebo arm all comparisons among NR and R patients 112 were confined to NDV-3A vaccinated subjects. For the in vitro studies, matched sera from pre-113 immune (day 0) and post-vaccination (day 14 or 28) patients or placebo control were compared.
115
Candida Strain 116 C. albicans SC5314 is a well characterized strain, and was the source of the N-terminus of Als3 117 used to develop the NDV-3A vaccine (17). Routinely, the organism was cultured overnight in 118 yeast peptone dextrose (YPD) broth (Difco) at 30 o C with shaking prior to use for in vitro assays.
119
To induce germination, C. albicans blastospores (5 x 10 6 ) were grown in RPMI 1640 with L-120 glutamine (Gibco BRL) for 1 h at 37 o C. For in vivo studies, C. albicans was serially passaged 121 overnight 3 times in YPD before challenge in mice. In all studies, C. albicans cells were washed 122 twice with endotoxin-free Dulbecco's PBS, suspended in PBS or yeast nitrogen base (YNB, Difco) 123 and counted with a hemocytometer to prepare the final inoculum.
125
Analysis of Sera Components
126
Als3p antibody titers in sera were measured using an ELISA assay as previously described (13).
127
To inactivate complement, aliquots of patient sera were independently heated at 55 o C for 1 h, 128 added to wells containing C. albicans in Yeast Nitrogen Base (YNB) medium, and incubated for 129 24 h at 37 o C to permit biofilm development. To adsorb anti-C. albicans antibodies, the sera were 130 incubated with C. albicans germ tubes for 1 h with gentle shaking at room temperature. The 131 mixture was centrifuged at 21,000 g prior to using the cell-free supernatant in the biofilm assay.
132
The presence and/or extent of removal of anti-Als3 antibodies (total IgG, IgG1 and/or IgG2) was Adhesion and biofilm formation were measured in 96-well polystyrene microtiter plates as 144 previously described (19) . Briefly, a 95 µL of C. albicans blastospores (2×10 5 cells/ml in YNB 145 medium) was added to wells containing 5 µL of patient serum (5% serum vol/vol), and incubated 146 I n r e v i e w at 37°C. Control wells had no serum. After 2 h, wells were washed twice with PBS and the extent 147 of adhesion was quantified by XTT assay (490 nm) (20). In parallel, cells were grown in the 148 presence of 5% serum for 24 h to promote biofilm formation. Biofilms were washed twice prior to 149 examining by bright field microscopy and quantification by XTT assay (20) . Formation of biofilm 150 on the catheter material silicone elastomer (SE) was also assessed (19). Briefly, circular SE pieces 151 were pre-incubated with fetal bovine serum overnight at 25 o C, washed twice and then introduced 152 into the wells. The biofilm assay was conducted as above, in the presence or absence of patient 153 sera.
155
Invasion Assay 156 The human Ect1/E6E7 vaginal epithelial cell line was maintained in keratinocyte serum-free 157 medium (Gibco) supplemented with bovine pituitary extract, epidermal growth factor, 158 penicillin/streptomycin and passaged every 3-4 days as previously described (21). To study the 159 effect of patient sera on C. albicans invasion, fibronectin-coated plastic coverslips were placed in 160 a 24-well plate and the cells allowed to adhere overnight. After two washes, C. albicans cells were 161 added to wells (fungus:host cell ratio of 5:1) for 12 h in the presence or absence of 5% patient Paque Plus reagent (Amersham Biosciences) (12). Neutrophils were incubated with C. albicans 176 germ-tubes containing YNB with 5% serum at 37 o C without shaking (neutrophil:fungus ratio, 5:1).
177
Controls contained C. albicans without neutrophils. After 90 min, the mixtures were sonicated to 178 disrupt neutrophils and the surviving fungi quantitatively cultured. The percentage of 179 opsonophagocytic killing (OPK) was calculated by dividing the number of CFU in the tubes 180 containing neutrophils by the number of CFU in tubes without neutrophils.
182
Statistical Analysis
183
All in vitro studies were performed in triplicate at a minimum, with two biological replicates. We analyzed the antibody titers of sera from R or NR patient in an attempt to understand the partial 203 protection elicited by NDV-3A vaccine. We conducted an area under the curve (AUC) analysis of 204 the total IgG titers of sera collected from NDV-3A vaccinated subjects over the 12-month period.
205
AUC of total IgG titers from NR patients was significantly higher than those in sera from R patients 206 during the early time points of collection (Day 0-90) (Figure 1A) . Similarly, the geometric mean 207 of IgG titers of the NR patients at 14 or 28 days post vaccination was approximately twice as high 208 as that detected in R patients ( Figure S1 in Supplemental Material). At later time points (Days 90-209 360), and despite the general drop in Ab titers for both patient populations, the difference in AUC 210 titers of the NR vs. R patients was even greater (Figure 1B) . Importantly, while the vast majority 211 of placebo patients had first recurrence within the first 90 days post vaccination (median recurrence 212 of 53 days), most of the vaccinated subjects had their first recurrence later than this (median 213 recurrence of 94 days) ( Figure 1C) . Consistent with the Phase 1b/2a clinical trial (16), the 214 enhanced time to recurrence was significant among vaccinees who are <40 years old (p= 0.043).
215
Interestingly, the later recurrence corresponded with the decreased IgG levels beyond 90 days.
217
In parallel, the serum antibody profiles were evaluated for anti-Als3 IgG subclasses. The IgG1 218 subclass comprised the predominant isotype in vaccinated NR and R sera (NR vs R IgG1 titer, 219 p=0.9, data not shown). Remarkably, the IgG2 titer in NR sera was much higher than in the R 220 patient sera (Figure 1D) , suggesting an isotype-specific enrichment in NR immune responses.
221
Titers of IgG3 and IgG4 were not significantly different in sera of R vs. NR patients (data not 222 shown). Also, we did not find any differences among IFN-Ɣ or IL-17 levels between R vs. NR Post-vaccination sera from NR subjects that received NDV-3A significantly reduced adhesion of 230 C. albicans to plastic, compared to pre-vaccination sera from the same patients (Figure 2A) . In 231 contrast, post-vaccination sera obtained from R patients that received NDV-3A did not 232 significantly alter C. albicans adhesion relative to pre-vaccination sera (Figure 2B) . As expected, 233 sera from patients who received the placebo did not influence C. albicans adhesion to plastic 234 (Figure 2C) . Sera from the NR-NDV-3A cohort was the only one that significantly reduced 235 adhesion, compared to the other two groups (Figure 2D) .
237
Sera from NR Patients Reduced C. albicans Biofilm Development
238
Post-vaccination sera from NR subjects who received NDV-3A reduced biofilm development as 239 compared to their paired pre-vaccination sera (Figure 3A) . This reduction was not observed when 240 cells were incubated with sera from R subjects who received NDV-3A or sera from placebo 241 recipients (Figure 3B, C) . As in the adhesion assay, a significantly greater reduction in biofilm 242 formation was observed in sera from NR versus R patients that received NDV-3A or placebo 243 recipients (Figure 3D) . 244 
I n r e v i e w
Bare-plastic is the gold-standard to measure biofilm formation (20) . We wanted to confirm that 245 sera samples that prevented biofilm formation on bare-plastic also prevent biofilm formation on 246 SE used in manufacturing catheters. Thus, antisera of NR patients displaying the highest extent of 247 biofilm inhibition were tested for their ability to impede biofilm formation on SE. These sera 248 reduced C. albicans biofilm formation on the SE substrate to an extent similar to that observed in 249 96 well-plates ( Figure S3 in Supplemental Material).
251
Consistent with reduction in biofilm formation, wells containing post-vaccination sera from NR 252 patients also displayed reduced C. albicans adhesion by bright field microscopy, as depicted by 253 reduced density of cells in the bottom of the wells (Figure 4A) . This reduction in adhesion to (Figure 4A) .
259
Sera from NR Patients Reduced C. albicans Invasion of Vaginal Epithelial Cells
260
Although sera preventing adhesion and biofilm formation were predominantly from the NR group, 261 some R and placebo subject sera also impeded these C. albicans virulence functions. Therefore, 262 sera from the three patients exhibiting the greatest inhibitory effect in each group were compared 263 for pre-and post-vaccination impact on C. albicans capacity to invade vaginal epithelial cells 264 ( Figure S5 in Supplemental Material). Antisera from NR patients reduced C. albicans invasion of 265 epithelial cells by ~53%, approximately two-fold higher than inhibition displayed by antisera of R 266 patients (24%) (Figure 4B) . The sera from placebo patients did not inhibit Candida invasion in 267 this assay (Figure 4B) . To determine whether anti-C. albicans antibodies were the active constituent of serum, we 278 incubated the pre-and post-sera with C. albicans germ tubes to adsorb antibodies against Als3.
279
This process will adsorb antibodies targeting all surface proteins that are expressed on C. albicans 280 germ tubes including those targeting Als3p. Indeed, ELISA plates coated with rAls3p for both day 281 0 and post-vaccination confirmed that the absorption process significantly reduced the anti-Als3 282 IgG titers in the samples ( Figure S6 in Supplemental Material). Next, these sera were used in C. 283 albicans biofilm assays as detailed above. Adsorption of antibodies from post-vaccination serum 284 reduced their ability to inhibit biofilm formation (Figure 5B) . 287 We questioned whether such functionally active sera influenced interactions of the fungus with 288 neutrophils from unvaccinated human volunteers ex vivo. As displayed in Figure 5C , sera from 289 NR patients enhanced neutrophil killing of fungal cells, compared to sera from R or P patients.
286
Sera from NR Patients Enhanced Neutrophil-Mediated Killing of C. albicans
290
I n r e v i e w
We also determined whether sera from NR patients that demonstrated the highest reduction in C. 291 albicans adhesion to plastic also exhibited the highest level of neutrophil-mediated killing. We 292 found a strong correlation between the ability of sera from NR patients to reduce adhesion and 293 increased neutrophil-mediated killing (p<0.05 and R 2 of 0.66). Further, overall larger numbers of 294 NR patients (13 NR subjects) induced OPK and prevented adhesion than the R group (13 subjects) 295 (Figure 5D and Figure S7 in Supplemental Material). In this study, we had the unique opportunity to compare humoral immune responses in patients 313 who derived a measurable health benefit from the NDV-3A vaccine versus those who did not, and 314 versus placebo patients. In addition, sera from R vs. NR subjects could be compared for their 315 ability to impede key virulence functions of C. albicans in vitro. The study goals were to explore 316 potential surrogate biomarkers of protection that might be useful in future studies of this and more 317 serious Candida infections and to gain insight into the potential mechanism(s) contributing to 318 protective efficacy of the vaccine. Our studies focused on determining the impact of serum 319 antibodies on selected putative virulence factors of C. albicans for three reasons: 1. The NDV-3 320 vaccine (based on C. albicans Als3 antigen with 6X His tag) induced high antibody titers (13); 2.
321
High antibody titers predict NDV-3 vaccine efficacy in mice (23); and 3. Antibodies, including 322 those targeting Hyr1p (24, 25), Sap2 (26), and Candida cell wall glycopeptides (27, 28) , protect 323 against experimental candidiasis. We focused also on Candida adhesion and invasion of vaginal 324 epithelial cells, as well as biofilm formation, since Als3p is a known mediator of these putative 325 virulence functions (10, 11, 29) .
327
NR patients maintained a high antibody median titer (AUC) of >25,000, while R patients had a 328 median AUC titer of 10,000 after 90 days post vaccination. This temporal waning of antibody 329 response coincided with the increased frequency to first relapse in R patients. The decrease in 330 antibody titer raises the possibility that R patients may benefit from a booster dose following 331 priming with the vaccine. There was also a significant increase in IgG2 subclass titers in NR 332 patients that received NDV-3A as compared to the R patients that received the vaccine, suggesting 333 that this IgG subclass may be a surrogate marker of protection post-vaccination. Human IgG2 and 334 IgG4, but not IgG1 or IgG3, have been reported to protect mice against Cryptococcus 335 neoformans infection (30), most likely by enhancing the fungicidal activity of macrophages (31).
336
Based on our current data, it is possible that the IgG2 subclass antibody component could impair 337 C. albicans interactions with host tissues, and contribute to neutrophil activation leading to 338 enhanced C. albicans killing by NR antisera. However, an important alternative hypothesis is also 339 of interest, that IgG2 and IgG4 antibody are surrogates for non-inflammatory skewing of immune 340 responses, biasing against symptoms of relapse.
342
Sera from NR patients that received NDV-3A significantly reduced C. albicans adherence to 343 plastic and SE, and impeded invasion of vaginal epithelial cells by C. albicans hyphae more than 344 antisera obtained from R patients that received NDV-3A or those from placebo. Biofilm formation 345 is a function of the ability of C. albicans to adhere to abiotic surfaces. Thus, it was not unexpected 346 that higher levels of anti-Als3 antibodies, as seen in antisera from NR patients but not R patients, 347 would also significantly reduced Candida biofilm formation. As determined from antibody 348 adsorption and complement inactivation studies, such abrogation of these C. albicans virulence 349 functions was due, at least in part, to anti-Als3p antibodies and did not require complement 350 fixation.
352
Our group previously demonstrated that NDV-3 protects mice from VVC by a mechanism that 353 involves priming of both B cell-and T cell-mediated adaptive immune responses (12).
354
Specifically, anti-Als3p antibodies enhanced the ex vivo killing of C. albicans by neutrophils 355 primed with . Although in the current study we could not detect a correlation between concordant with the finding that RVVC is a disease in which a discordance of exacerbated 360 neutrophil influx often occurs in the face of inefficiency in clearing the infection (32) (33) (34) . We 361 postulate that in NR women, the vaccine was able to induce an antibody response that; 1) protected 362 against C. albicans adherence to and invasion of mucocutaneous barriers; 2) reduced the capability 363 of the organism to form biofilm from which persistent infection occurs; 3) induced a coordinated 364 phagocyte response that is more efficacious in clearing the infection; and/or 4) modulated 365 profusive inflammatory responses of the host associated with relapse.
367
The statistical robustness of the in vitro assays of IgG2, adhesion, biofilm formation and neutrophil 368 killing which were validated in our ROC analyses, revealed that any of these tests could be used 369 as biomarkers of vaccine efficacy. While the latter three assays are likely too cumbersome to 370 support larger clinical trials, an ELISA measuring IgG2 in the sera of vaccinated patients would 371 be a simple yet robust method to predict the protective efficacy of a vaccine in a human clinical 372 study like the current one, or future studies on disseminated candidiasis.
374
Our forthcoming studies are planned to precisely define the roles of antibody isotypes, the impact 375 of boosting, the combination of multiple antigen vaccines, and the influence of advanced adjuvants 376 to further optimize vaccine and immunotherapeutic strategies targeting Candida species. of the total IgG titers over time (0-90 and 90-360 days) for each patient, in the NR and R NDV-3A-510 vaccinated subjects was plotted. In the first 3 months post-vaccination, AUC of NR patients was 511 significantly higher (p=0.046) than that of R patients (A). In months 3 -12, this difference in AUC was 512 also significant (p=0.022) (B). The decrease in AUC of the IgG titers in R patient sera in the later months 513
corresponded with the increase in recurrent episodes of VVC during this period (C). Finally, significantly 514 more number of NR patients displayed IgG2 antibodies in their sera, also mean (geometric) IgG2 antibody 515 titer was higher in NR patients, compared to R patients ( placebo and 6 NDV3-A vaccinated patients (3 R and 3 NR) whose sera showed the highest reduction in 538 biofilm formation, and were chosen for the vaginal epithelial cell invasion assay presented in Figure 3B . that post-vaccination sera from NR patients that abrogated biofilm formation displayed short and wavy 544
hyphae, compared to the normal robust hyphae in the biofilms formed in pre-vaccination serum, or the 545 control commercial pooled human serum (A). Six samples from placebo or NDV-3A vaccinated patients 546
(3 R and 3 NR) were selected from Figure 2D (open symbols) for analysis in invasion of vaginal epithelial 547 cells. Post vaccination sera from NR patients inhibited invasion of vaginal epithelial cells two-fold more 548 than R patient or P patient sera (B). **P <0.01 for post-vs. pre-vaccination sera from R patients. + P <0.05 549
for post-vaccination sera vs. pre-vaccination sera from NR and vs. post-vaccination sera from R or placebo 550
patients. Data in B are presented as mean + SD. 551 552 Figure 5 . Assessment of the role of antibodies in affecting virulence, and evaluation of OPK of C. 553 albicans germ tubes in the presence of patient sera. Heat treatment of post-vaccination sera from NR 554 patients does not significantly reduce its biofilm-inhibitory activity, compared to paired untreated sera (A).
555
Adsorption of antibodies in post-vaccination sera from NR patients with C. albicans germ tubes 556 significantly (p=0.03) abolishes the biofilm inhibitory activity of the sera, when compared to paired 557 I n r e v i e w adsorbed pre-vaccination sera. Only post-vaccination sera from NR patients significantly (p=0.03) enhance 558
OPK and killing of C. albicans germ tubes by human neutrophils, compared to post-vaccination sera from 559 R or P patients (C). A comparison between percent increase in OPK activity and percent reduction in 560 adhesion, in post-vaccination sera from NR and R patients, resulted in significant correlation within the 561 respective subject sera (D) . Each open circle represents individual NR sera, which displayed both an overall 562 greater reduction in adhesion and increase in neutrophil killing. Solid circles denote the individual R 563
patients that compared to the NR patients, show a smaller % decrease in adhesion as well as neutrophil 564
killing. Negative values on the graph represent % increase in adhesion or % decrease in neutrophil killing. 565 566 Figure 6 . ROC analysis of the in vitro assays. An ROC analyses for four in vitro studies was performed 567
on GraphPad Prism software, where a graph was generated of 100% -(minus) Specificity% versus 568
Sensitivity % for each of the assays: IgG2 titers (A), adhesion (B), biofilm formation (C) and neutrophil 569 killing (D). For each graph, an Area Under the Curve (Area), standard error of the AUC under the ROC 570 curve, as well as the 95% confidence interval is reported. A p-value of <0.05 in each of the ROC curves 571
concludes that the results are significant, and robust. 572 573
